BusinessPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target ToxicitiesBy Nasdaq OMXApr 3, 2017, 12:05 PM UTC
